LEXT invests in Psy Integrated
929 Mainland Street
Vancouver, BC V6B 1S3
Phone
Fax
(604) 928-8913
(604) 628-0129
Email [email protected]
Website www.lexston.ca
NEWS RELEASE
LEXSTON LIFE SCIENCES CORP. MAKES AN INVESTMENT INTO PSY INTEGRATED HEALTH INC.
Vancouver, British Columbia, July 7, 2021. Lexston Life Sciences Corp. (CSE: LEXT) (the “ Company” or
“Lexston”) is pleased to announce an acquisition of 750,000 Class C Non - Voting Common Shares of Psy
Integrated Health Inc. (“Psy Integrated”) for the total consideration of $ 75,000 representing 13% of the
total issued and outstanding shares of Psy Integrated.
Founded in 2020 Psy Integrated is a British Columbia based benefit corporation with a mission to improve
the mental health of Canadians through psychedelic assisted therapies delivered by a network of clinics
delivering integrative health.
Psy Integrated’s flagship Empower Health clinic in Vancouver includes a multi-disciplinary team of highly
experienced health practitioners offering telehealth and onsite services to their patients from its location
in Vancouver, British Columbia, with additional clinics planned.
Psy Integrated also offers a broad range of managed services to member clinics including:
• Clinic Practices – develop therapeutic protocols for use of psychedelic medicines by integrative
health clinics and practitioners
• Compliance – establish controlled substance protocols for clinics
• Supply – identify appropriate sources for legal psychedelic medicines for clinics
“This first investment in Psy Integrated marks the beginning of our accelerated plan to play an integral
role in providing patients with caring and meaningful access to health and wellness thr ough the use of
psychedelics” stated Jag Bal, CEO of Lexston . Mr. Bal added: “We understand that the critical path to
success lies both within our own work and research, as well as collaboration with companies such as Psy
Integrated.”
About Lexston Life Sciences Corp.
Lexston Life Sciences Corp. is a Canadian biotechnology company providing cannabis testing and research
services. Lexston is also in the process of securing licensing under the exemptions prescribed by section
56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of its services into the
psychedelic industry with an initial focus on the detection and quantification of psychedelic molecules in
the lab and point of care. Lexston intends to develop and validate methods for standardized
manufacturing of plant derived psychedelics in support of burgeoning trials in the field of mental health
and wellness.
Page | 2
On Behalf of the Board of Directors
LEXSTON LIFE SCIENCES CORP.
Jagdip Bal Chief Executive Officer
Telephone: (604) 928-8913
Forward Looking Information
This release includes forward-looking information within the meaning of Canadian securities laws
regarding Lexston and Psy Integrated and their respective businesses. Such statements are based on the
current expectations and views of future events of the management of each entity and are based on
assumptions and subject to risks and uncertainties. Although the management of each entity believes
that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The
forward-looking events and circumstances discussed in this release could differ materially as a result of
known and unknown risk factors and uncertainties affecting the companies, including market conditions,
economic factors, management's ability to manage Lexston an d Psy Integrated and the equity markets
generally.
Although Lexston and Psy Integrated have attempted to identify important factors that could cause actual
actions, events or results to differ materially from those described in the forward-looking statements,
there may be other factors that cause actions, events or results to differ from tho se anticipated,
estimated or intended. Accordingly, readers should not place undue reliance on any forward -looking
statements or information. No forward -looking statement can be guaranteed. Except as required by
applicable securities laws, forward-looking statements speak only as of the date on which they are made
and Lexston and Psy Integrated do not undertake any obligation to publicly update or revise any forward-
looking statement, whether as a result of new information, future events, or otherwise.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for
the adequacy or accuracy of this release.